Full text PDF - International Policy Network

Sources 293
Wofford, D., & Shanahan, C., (2004), Doing Business in 2005, World Bank.
5 Increasing access to medicines
Adams, C., & Brantner, V., (2003), “New Drug Development: Estimating Entry form
Human Clinical Trials,” Federal Trade Commission, working paper 262.
Attaran, A., (2004), “How Do Patents and Economic Policies Affect Access to Essential
Medicines in Developing Countries”, Health Affairs, 23:3, 155–66.
Barat, L., Palmer, N., Basu, S., Worrall, E., Hanson, K., Mills, A., (2003), “Do Malaria
Control Interventions Reach the Poor?: A view Through the Equity Lens,” Disease
Control Priorities Project, Bethesda: National Institutes of Health.
Bate, R., Tren, R. & Urbach, J., (2005), Taxed to death, Washington DC: AEI-Brookings
Joint Center for Regulatory Studies.
Carrin, G., (2002), “Social Health Insurance in developing countries: a continuing
challenge,” International Social Security Review, Vol. 55.
Castro-Leal, F., Dayton, J., Demery, L. & Mehra, K., (1999), “Public Social Spending in
Africa: Do the Poor Benefit?” World Bank Research Observer, 14(1):49–72.
CMR International Institute for Regulatory Science, (2004), The changing regulatory
environment: reality and perception, R&D briefing no. 42.
Danzon, P. & Furukawa, M., (2003), “Prices And Availability of Pharmaceuticals:
Evidence From Nine Countries,” Health Affairs, W3: 521–536.
Danzon, P., Wang, Y. & Wang, L., (2003), The impact of drug price regulation on the
launch of delay of new drugs-evidence from 25 major markets in the 1990s,
National Bureau of Economic Research, working paper 9874.
Deolalikar, A., (1995), “Government Health Spending in Indonesia: Impact on
Children in Different Economic Groups.” In Public Spending and the Poor: Theory
and Evidence, eds. Van de Walle, D., & Nead, K., Baltimore: John Hopkins
University Press.
DiMasi, J., (1995), “Trends in Drugs Development Costs, Times and Risks,” Drug
Information Journal, 29.
DiMasi, J., Jansen, R., & Grabowski, H., (2003), “The Price of innovation: new
estimates of drug developments costs,” Journal of Health Economics, 22: 151–185.
Department of Health and Human Services, United States, (2002), “Report to the
President: Prescription drug coverage, spending, utilization, and prices.”
de Soto, H., (2001), The Mystery of Capital, London: Bantam Books.
Dranover, D., & Meltzer, D., (1994), “Do Important Drugs reach the Market Sooner?”
The RAND Journal of Economics, 25(3): 402–423.
Dussault, G., & Dubois, C., (2003), Human resources for health policies: a critical
component in health policies, Human Resources for Health.
European Commission, (2003), Working Document on developing countries’ duties and
taxes on essential medicines used in the treatment of major communicable diseases,
European Commission, Directorate-General for Trade.
Filmer, D. & Pritchett, L., (1999), “The Impact of public spending on health: does
money matter?” World Bank.
Filmer, D., Hammer, J., Pritchett, L., (2000), “Weak links in the chain: a diagnosis of
health policy in poor countries,” World Bank Research Observer, 15(2): 199–224.